{"entity":{"id":"apollomics","kind":"company","name":"Apollomics","aka":["Apollomics Inc.","Apollomics (Hangzhou)"],"tldr":"Apollomics is a US-Chinese company whose MET inhibitor vebreltinib is approved in China for MET exon 14 lung cancer through its partner Avistone, and whose E-selectin antagonist uproleselan failed in acute myeloid leukaemia in 2024.","summary":"Apollomics, based in Foster City, California with operations in Hangzhou and listed on Nasdaq since a 2023 merger, licenses and develops cancer drugs. Vebreltinib (APL-101, bozitinib), a selective MET inhibitor, is approved in China for MET exon 14 skipping non-small-cell lung cancer via Avistone; the phase 3 trial of uproleselan, an E-selectin antagonist licensed from GlycoMimetics, with chemotherapy in relapsed acute myeloid leukaemia missed its survival endpoint in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.apollomicsinc.com"},{"label":"ClinicalTrials.gov: trials led by Apollomics","url":"https://clinicaltrials.gov/search?lead=Apollomics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","aml"],"sections":["targeted-therapy"],"technologies":[],"targets":["met"],"drugs":["vebreltinib"],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03175224"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Foster City, CA","country":"US","companyType":"biotech","website":"https://www.apollomicsinc.com","stage":"public","investors":[],"funding":[]},"route":"/companies/apollomics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"drug":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"company":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/"}],"trial":[{"id":"nct03175224","kind":"trial","name":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","route":"/trials/nct03175224/"}]}}